Roy D. Baynes, Director at Travere Therapeutics, Inc. (TVTX), sold 4,500 shares at $46.65 ($210K) on 2026-05-05, disclosed to the SEC on 2026-05-06.
Scheduled sale ($210k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| TVTX | SELL | 2026-04-16 | $1.4M | — | Filing → |
| TVTX | SELL | 2026-04-07 | $330K | — | Filing → |
| NTRA | SELL | 2025-11-21 | $4.6M | — | Filing → |